
Opinion|Videos|December 29, 2025
First- and Second-Generation Antipsychotic Therapies and Treatment Sequencing
Panelists discuss how thoughtful sequencing of antipsychotics enhances adherence, safety, and long-term efficacy.
Advertisement
Episodes in this series

Panelists discuss how first-generation antipsychotics primarily manage positive symptoms but often cause extrapyramidal adverse effects, while second-generation options offer broader efficacy with improved tolerability.
Panelists discuss how choosing between oral and long-acting injectable formulations depends on patient adherence history, preference, and adverse effect risk.
Panelists discuss how careful sequencing and cycling through medications should minimize relapse risk while balancing safety, efficacy, and patient satisfaction.
Advertisement
Related to this article

Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.

Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.

An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.

Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.

Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5

